One patient with suspected GC was studied after his informed consent was obtained. MR imaging and MRS were performed with a 1.5-T unit (Avanto®, Siemens Medical Systems, Erlangen, Germany). A localizing Sagittal T1-weighted image was obtained, followed by Axial and Coronal T1-weighted. Axial T2-weighted as well as DARK FLUID or FLAIR images were also acquired. The hybrid Multivoxel 2D Chemical Shift Imaging (CSI) technique uses a Point-Resolved Spectroscopy (PRESS) Double Spin Echo scheme for pre-selection of a Volume of Interest (VOI) that is usually defined to include the abnormality as well as normal appearing brain tissue. We use CHESS for water suppression. In order to avoid a contribution to the spectra from fat signals, the VOI was completely enclosed within the brain and positioned at the center of the phase-encoded Field of View (FOV). VOI consists of an 80 mm x 80 mm region placed within a 160 mm x 160 mm FOV on a 10 mm to 20 mm slice. A 16 x 16 phase-encoding matrix gives an 8 x 8 array of spectra in the VOI with a plane resolution of 10 mm x 10 mm. The parameters used were 1500/30/6 (TR/TE/Acquisitions). Other settings included were a Hamming filter, number of sampling points NP = 1024, BW = 1kHz, preparatory scans = 6, delta frequency = -2.7 ppm. Data underwent apodization through a 1.0 Hz Lorentzian filter, Fourier transformation in time and space, and phase correction. Lipids (Lip), Lactate (Lac), N-Acetylaspartate (NAA), Creatine (Cr), Choline (Cho) and myo-Inositol (mI) intensity signals were detected. NAA/Cr, Cho/Cr, mI/Cr and Cho/NAA ratios were calculated. The GC diagnosis was confirmed by a stereotactic biopsy at the area where Cho/Cr ratio reached the highest value which is represented as an intense red area within the metabolic map showed in Figure 1.